吉西他滨联合奥沙利铂和地塞米松治疗复发或难治性非霍奇金淋巴瘤的疗效观察  

Efficacy of Gemcitabine Combined with Oxaliplatin and Dexamethasone Regi-men on Relapsed or Refractory Non-Hodgkin's Lymphoma

作　　者：黄燕[1] 李午平[1] 

机构地区：[1]江西省肿瘤医院内一科,南昌330029

出　　处：《航空航天医学杂志》2013年第11期1308-1310,共3页Journal of Aerospace medicine

摘　　要：目的：观察吉西他滨联合奥沙利铂和地塞米松方案治疗复发或难治性非霍奇金淋巴瘤的近期疗效和毒性反应。方法：吉西他滨1000mg／m^2，静脉滴注，第1、8d；奥沙利铂130mg／m^2，静脉滴注，第1d；地塞米松20mg／d，静脉滴注，第1—5d；21～28d为1周期，连用2个周期以上评价疗效。结果：全组38例，总有效率为68．42％，其中完全缓解（CR）10例（26．32％），部分缓解（PR）16例（42．10％）。不良反应主要为Ⅰ-Ⅲ度骨髓抑制和轻至中度胃肠道反应。结论：吉西他滨联合奥沙利铂和地塞米松方案治疗复发或难治性非霍奇金淋巴瘤安全有效，值得临床推广。Abstract Objective：To evaluate the efficacy and toxicity of gemcitabine combined with oxaliplatin and dexamethasone regimen for patients with relapsed or refractory Non - Hodgkin＇s lymphoma. Methods：Gemcitabine 1 000 mg/m^2, ivgtt on dl and d8 ;oxaliplatin 130 mg/m^2, ivgtt on d1 ;dexamethasone 20 mg/d, ivgtt,on dl to d5; 21 -28 days consisted of one cycle, and all the patients received over two cycles of the chemotherapy. Results：In 38 cases, the overall response rate was 68.42%. There was a complete response in 10 cases （26. 32% ） ,partial response in 16 cases （42. 10% ）. Main toxicity were Ⅰ-Ⅲ degree bone marrow depression and mild gastrointestinal reactions. Conclusions ： Gemcitabine combined with oxaliplatin and dexamethasone regimen was safe and effective in the treatment of relapsed or refractory Non - Hodgkin＇s lymphoma. Worthy of clinical application.

关 键 词：非霍奇金淋巴瘤 复发或难治性 吉西他滨 奥沙利铂 地塞米松 

分 类 号：R733.1[医药卫生—肿瘤]